Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396163

2023-01-01

Abstract:PDF file - 343K, p53 function in BRAFV600E/ARF-/- murine melanoma cells.

What problem does this paper attempt to address?

Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396166

2023-01-01

Abstract:PDF file - 155K, Tumor formation in BRAFV600E/ARF-/- mice.
Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396160

2023-01-01

Abstract:PDF file - 407K, DNA damage induced by BRAFV600E in human melanoma cells.
Supplementary Table 1 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396157

2023-01-01

Abstract:PDF file - 23K, Primer sequences.
Data from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.c.6504488.v1

2023-01-01

Abstract:AbstractBoth genetic mutations and UV irradiation (UVR) can predispose individuals to melanoma. Although BRAFV600E is the most prevalent oncogene in melanoma, the BRAFV600E mutant is not sufficient to induce tumors in vivo. Mutation at the CDKN2A locus is another melanoma-predisposing event that can disrupt the function of both p16INK4a and ARF. Numerous studies have focused on the role of p16INK4a in melanoma, but the involvement of ARF, a well-known p53 activator, is still controversial. Using a transgenic BRAFV600E mouse model previously generated in our laboratory, we report that loss of ARF is able to enhance spontaneous melanoma formation and cause profound sensitivity to neonatal UVB exposure. Mechanistically, BRAFV600E and ARF deletion synergize to inhibit nucleotide excision repair by epigenetically repressing XPC and inhibiting the E2F4/DP1 complex. We suggest that the deletion of ARF promotes melanomagenesis not by abrogating p53 activation but by acting in concert with BRAFV600E to increase the load of DNA damage caused by UVR. Cancer Res; 73(14); 4337–48. ©2013 AACR.
Loss Of Arf Sensitizes Transgenic Braf(V600e) Mice To Uv-Induced Melanoma Via Suppression Of Xpc

Chi Luo,Jinghao Sheng,Miaofen G Hu,Frank G Haluska,Rutao Cui,Zhengping Xu,Philip N Tsichlis,Guo-Fu Hu,Philip W Hinds

DOI: https://doi.org/10.1158/0008-5472.CAN-12-4454

IF: 11.2

2013-01-01

Cancer Research

Abstract:Both genetic mutations and UV irradiation (UVR) can predispose individuals to melanoma. Although BRAF(V600E) is the most prevalent oncogene in melanoma, the BRAFV600E mutant is not sufficient to induce tumors in vivo. Mutation at the CDKN2A locus is another melanoma-predisposing event that can disrupt the function of both p16(INK4a) and ARF. Numerous studies have focused on the role of p16(INK4a) in melanoma, but the involvement of ARF, a well-known p53 activator, is still controversial. Using a transgenic BRAF(V600E) mouse model previously generated in our laboratory, we report that loss of ARF is able to enhance spontaneous melanoma formation and cause profound sensitivity to neonatal UVB exposure. Mechanistically, BRAF(V600E) and ARF deletion synergize to inhibit nucleotide excision repair by epigenetically repressing XPC and inhibiting the E2F4/DP1 complex. We suggest that the deletion of ARF promotes melanomagenesis not by abrogating p53 activation but by acting in concert with BRAF(V600E) to increase the load of DNA damage caused by UVR. (C) 2013 AACR.
Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Gongda Xue,Reto Kohler,Fengyuan Tang,Debby Hynx,Yuhua Wang,Francesca Orso,Vincent Pretre,Reto Ritschard,Petra Hirschmann,Peter Cron,Tim Roloff,Reinhard Dummer,Mario Mandala,Sandrine Bichet,Christel Genoud,Alexandra G. Meyer,Manuele G. Muraro,Giulio C. Spagnoli,Daniela Taverna,Curzio Ruegg,Taha Merghoub,Daniela Massi,Huifang Tang,Mitchell P. Levesque,Stephan Dirnhofer,Alfred Zippelius,Brian A. Hemmings,Andreas Wicki

DOI: https://doi.org/10.18632/oncotarget.18213

2017-01-01

Oncotarget

Abstract:BRAF inhibitors (BRAFi) and the combination therapy of BRAF and MEK inhibitors (MEKi) were recently approved for therapy of metastatic melanomas harbouring the oncogenic BRAFV600 mutation. Although these therapies have shown pronounced therapeutic efficacy, the limited durability of the response indicates an acquired drug resistance that still remains mechanistically poorly understood at the molecular level. We conducted transcriptome gene profiling in BRAFi-treated melanoma cells and identified that Mer tyrosine kinase (MerTK) is specifically upregulated. MerTK overexpression was demonstrated not only in melanomas resistant to BRAFi monotherapy (5 out of 10 samples from melanoma patients) but also in melanoma resistant to BRAFi+MEKi (1 out of 3), although MEKi alone does not affect MerTK. Mechanistically, BRAFi-induced activation of Zeb2 stimulates MerTK in BRAFV600 melanoma through mTORC1-triggered activation of autophagy. Co-targeting MerTK and BRAFV600 significantly reduced tumour burden in xenografted mice, which was pheno-copied by co-inhibition of autophagy and mutant BRAFV600.
Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Jin Zhang,Enshun Xu,Cong Ren,Hee Jung Yang,Yanhong Zhang,Wenqiang Sun,Xiangmudong Kong,Weici Zhang,Mingyi Chen,Eric Huang,Xinbin Chen

DOI: https://doi.org/10.1158/0008-5472.22417952

2023-01-01

Abstract:Supplemental Fig. S1 represents analysis of TLBL. Supplemental Fig. S2 contains representative images of H.E.-stained tumors. Supplemental Fig. S3 contains RT-PCR analysis of various genes (Tbet, NFAT1,NFAT2, IFNG, IL6) in thymus and TLBLs. Supplemental table S1-4 contains gender, survival, and tumor information of the mice.
Supplementary Figure 2 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446039.v1

2023-01-01

Abstract:PDF file - 1452K, Figure S2. Genetic mutations in exon 14 of PDGFRA.
Supplementary Figure 3 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.
Supplementary Figure 5B from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Jingqiang Wang,Takashi Kobayashi,Nicolas Floc'h,Carolyn Waugh Kinkade,Alvaro Aytes,David Dankort,Celine Lefebvre,Antonina Mitrofanova,Robert D. Cardiff,Martin McMahon,Andrea Califano,Michael M. Shen,Cory Abate-Shen

DOI: https://doi.org/10.1158/0008-5472.22394108

2023-01-01

Abstract:PDF file - 36K, Pathway enrichment analysis for differentially expressed genes between Nkx3.1CE2/+; Ptenf/f; BrafCA/+ and Nkx3.1CE2/+; Ptenf/f mouse prostate tumors
Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chi,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruifeng Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036.v1

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.
Supplementary Figure 2 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Hongbin Ji,Zhenxiong Wang,Samanthi A. Perera,Danan Li,Mei-Chih Liang,Sara Zaghlul,Kate McNamara,Liang Chen,Mitchell Albert,Yanping Sun,Ruqayyah Al-Hashem,Lucian R. Chirieac,Robert Padera,Roderick T. Bronson,Roman K. Thomas,Levi A. Garraway,Pasi A. Jänne,Bruce E. Johnson,Lynda Chin,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22367991

2023-01-01

Abstract:Supplementary Figure 2 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models
Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Amanda Herzog,Yansong Bian,Robert Vander Broek,Bradford Hall,Jamie Coupar,Hui Cheng,Anastasia L. Sowers,John D. Cook,James B. Mitchell,Zhong Chen,Ashok B. Kulkarni,Carter Van Waes

DOI: https://doi.org/10.1158/1078-0432.22445265

2023-01-01

Abstract:PDF file - 1957K, Treatment in UM-SCC xenograft and Tgfbr1/Pten KO mice.
Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Lenka Sinik,Katherine A. Minson,John J. Tentler,Jacqueline Carrico,Stacey M. Bagby,William A. Robinson,Rotem Kami,Tal Burstyn‐Cohen,S. Gail Eckhardt,Xiaodong Wang,Stephen V. Frye,H. Shelton Earp,Deborah DeRyckere,Douglas K. Graham

DOI: https://doi.org/10.1158/1535-7163.22508884.v1

2023-01-01

Abstract:Supplemental Figure 2 shows impact of UNC2025 on colony forming potential.
Supplementary Figure 1 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Hongbin Ji,Zhenxiong Wang,Samanthi A. Perera,Danan Li,Mei‐Chih Liang,Sara Zaghlul,Kate McNamara,Liang Chen,Aaron P. Mitchell,Yi Sun,Ruqayyah Al-Hashem,Lucian R. Chirieac,Robert F. Padera,Roderick T. Bronson,Roman K. Thomas,Levi A. Garraway,Pasi A. Jänne,Bruce E. Johnson,Lynda Chin,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22367994.v1

2023-01-01

Abstract:Supplementary Figure 1 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models
Supplementary Figure 1 from the ARF Tumor Suppressor Inhibits Tumor Cell Colonization Independent of P53 in a Novel Mouse Model of Pancreatic Ductal Adenocarcinoma Metastasis

Viviane Palhares Muniz,J. Matthew Barnes,Seema Paliwal,Xuefeng Zhang,Xiaoyun Tang,Songhai Chen,Kokou D. Zamba,Joseph J. Cullen,David K. Meyerholz,Shari Meyers,J. Nathan Davis,Steven R. Grossman,Michael D. Henry,Dawn E. Quelle

DOI: https://doi.org/10.1158/1541-7786.22519164

2023-01-01

Abstract:Supplementary Figure 1 from The ARF Tumor Suppressor Inhibits Tumor Cell Colonization Independent of p53 in a Novel Mouse Model of Pancreatic Ductal Adenocarcinoma Metastasis
Supplementary Figure S1 from Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

Dominic Lapadula,Eduardo Farias,Clinita E. Randolph,Timothy J. Purwin,Dougan McGrath,Thomas H. Charpentier,Lihong Zhang,Shihua Wu,Mizue Terai,Takami Sato,Gregory G. Tall,Naiming Zhou,Philip B. Wedegaertner,Andrew E. Aplin,Julio Aguirre-Ghiso,Jeffrey L. Benovic

DOI: https://doi.org/10.1158/1541-7786.22513482

2023-01-01

Abstract:GNAQ and GNA11 sequence analysis of UM002B cells.
Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in Pten-Deficient Mice

Dan Freeman,Ralf Lesche,Nathalie Kertesz,Shungyou Wang,Gang Li,Jing Gao,Matthias Groszer,Hilda Martinez-Diaz,Nora Rozengurt,George Thomas,Xin Liu,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22365212.v1

2023-01-01

Abstract:Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in Pten-Deficient Mice

Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Table 1 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Data from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Loss Of Arf Sensitizes Transgenic Braf(V600e) Mice To Uv-Induced Melanoma Via Suppression Of Xpc

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 5B from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Supplementary Figure 1 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure 1 from the ARF Tumor Suppressor Inhibits Tumor Cell Colonization Independent of P53 in a Novel Mouse Model of Pancreatic Ductal Adenocarcinoma Metastasis

Supplementary Figure S1 from Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Table 1 from Loss of ARF Sensitizes Transgenic BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mice to UV-Induced Melanoma via Suppression of XPC